- Home
- CMPS vs CMPX Comparison
CMPS vs CMPX Comparison
Compare CMPS & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPS
- CMPX
- Stock Information
- Founded
- CMPS 2020
- CMPX 2014
- Country
- CMPS United Kingdom
- CMPX United States
- Employees
- CMPS N/A
- CMPX N/A
- Industry
- CMPS Biotechnology: Pharmaceutical Preparations
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- CMPS Health Care
- CMPX Health Care
- Exchange
- CMPS Nasdaq
- CMPX Nasdaq
- Market Cap
- CMPS 487.4M
- CMPX 576.5M
- IPO Year
- CMPS 2020
- CMPX N/A
- Fundamental
- Price
- CMPS $6.34
- CMPX $3.65
- Analyst Decision
- CMPS Strong Buy
- CMPX Strong Buy
- Analyst Count
- CMPS 7
- CMPX 7
- Target Price
- CMPS $17.00
- CMPX $14.71
- AVG Volume (30 Days)
- CMPS 1.5M
- CMPX 1.7M
- Earning Date
- CMPS 10-30-2025
- CMPX 11-11-2025
- Dividend Yield
- CMPS N/A
- CMPX N/A
- EPS Growth
- CMPS N/A
- CMPX N/A
- EPS
- CMPS N/A
- CMPX N/A
- Revenue
- CMPS N/A
- CMPX N/A
- Revenue This Year
- CMPS N/A
- CMPX N/A
- Revenue Next Year
- CMPS N/A
- CMPX N/A
- P/E Ratio
- CMPS N/A
- CMPX N/A
- Revenue Growth
- CMPS N/A
- CMPX N/A
- 52 Week Low
- CMPS $2.25
- CMPX $1.27
- 52 Week High
- CMPS $6.63
- CMPX $4.08
- Technical
- Relative Strength Index (RSI)
- CMPS 73.27
- CMPX 56.88
- Support Level
- CMPS $5.54
- CMPX $3.31
- Resistance Level
- CMPS $6.62
- CMPX $3.80
- Average True Range (ATR)
- CMPS 0.33
- CMPX 0.24
- MACD
- CMPS 0.08
- CMPX -0.01
- Stochastic Oscillator
- CMPS 86.39
- CMPX 70.51
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.